News/Genmab Announces TEPKINLY® (epcoritamab) in Comb…
GlobeNewswire🇪🇺 EUUnresolved

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S

Media Release COPENHAGEN, Denmark; July 6, 2026

Read full release on GlobeNewswire
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma